Searched for
ZYDUS LIFESCIENCES TARGET PRICE
Lenskart Solutions among 7 stocks hitting 52-week highs; surge up to 20% in a monthSeven BSE 200 stocks hit fresh 52-week highs as the Sensex gained 113 points. Paytm led with a 19% monthly rise, followed by Bosch, Lenskar...- Paytm management gets Sebi show cause notice over timing of 2023 loan disclosure announcementPaytm management has received a Sebi show-cause notice over the timing and classification of information disclosed in a December 2023 corpo...
- Astral shares rally 10% following Q1 results; Citi sees target price at Rs 1,900, Nuvama upgrades stock to 'Buy'Astral shares surged nearly 10% after strong Q1 FY27 results, with profit rising 51.8% YoY. Citi retained a Buy rating with a Rs 1,900 targ...
- Buy, Sell or Hold: Citi remains neutral on Lenskart; Nomura upgrades Tata Motors to buyBrokerages remain positive on select stocks, with Nomura upgrading Tata Motors’ commercial vehicle business to Buy and Citi retaining a Neu...
- F&O Radar: Call Ratio Spread strategy for SBI shares this weekState Bank of India has delivered a sideways range breakout supported by solid volumes, holding strong above key EMAs. Choice Broking recom...
- Stocks to buy in 2026 for long term: Siemens, Zydus Lifesciences among 5 stocks that could give 10-20% returnWe have collated a list of recommendations from top brokerage firms from ETNow and other sources
- MCX shares rise 2% as JPMorgan upgrades, raises target price after this Sebi proposalShares of Multi Commodity Exchange (MCX) rose more than 2% after Sebi proposed widening foreign portfolio investors’ access to physically s...
- Zydus Lifesciences shares drop 3% after Q1 earnings. Here's why Nuvama upgraded rating, hiked targetShares of Zydus Lifesciences saw a decline of more than two percent following the announcement of a notable profit drop. The net profit plu...
- Mid-cap stocks: Time for a change of stance? 6 mid-caps from different sectors with an upside potential up to 29%Sometimes the real market story is not in the headline index. The Nifty and Sensex can be under pressure, and yet, below them, mid- and sma...
- Zydus Lifesciences Q1 Results: Net profit down 36% at Rs 939.8 croreZydus Lifesciences reported a significant year-on-year decline of thirty-six percent in net profit for the first quarter, despite a robust ...
- Buy, Sell or Hold: Morgan Stanley remains overweight on Bharat Forge; Mirae Asset Sharekhan recommends buy on DEE Development EngineersBrokerages remain positive on select stocks following Q1 FY27 earnings, with Morgan Stanley retaining an Overweight rating on Bharat Forge ...
- Brokerages raise SBI target price after Q1 earnings beatState Bank of India shares faced a 2.2 percent decline on Monday, despite surpassing analysts' expectations for their June-quarter earnings...
- Independence Day 2026: India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decad...
- Hindalco share price: Why brokerages are reiterating their Buy calls, raising target prices after Q1 earningsHindalco shares fell despite the company reporting a record Q1 profit. However, brokerages remained bullish, citing strong India operations...
- Parag Parikh Flexi Cap Fund hikes stakes in HCL Tech, Coal India and 9 other stocks in July. Check full listParag Parikh Flexi Cap Fund, the largest active flexicap fund by AUM, raised its stake in HCL Technologies, Coal India and nine other stock...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- Buy, Sell or Hold: Elara Capital raises target price on BEML; Citi remains bullish on Titan CompanyBrokerages remain bullish on BEML, Titan and Fortis Healthcare, citing strong earnings, improving margins and growth prospects. Elara sees ...
- SBI shares rise nearly 2% after Q1 beat. Here's what Nomura, Morgan Stanley and other top brokerages expect nextSBI shares gained 1.55% after the lender reported a 10% YoY rise in Q1 FY27 standalone net profit to Rs 21,121 crore, beating Street estima...
- Swiggy shares jump nearly 3% as company targets Rs 10,000 crore adjusted EBITDA by FY31Swiggy shares rose after the company unveiled an ambitious FY31 roadmap targeting Rs 10,000 crore in Adjusted EBITDA. It aims to more than ...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThe price of crude oil is down again despite the escalating tensions in the Gulf region. That augurs well for markets. This does not mean t...
Load More
